{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:44:48Z","timestamp":1791902688495,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s13555-024-01260-7","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T04:02:02Z","timestamp":1725940922000},"page":"2759-2769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03732807","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jennifer","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8257-1816","authenticated-orcid":false,"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8571-2653","authenticated-orcid":false,"given":"Susan","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-7494","authenticated-orcid":false,"given":"Sergio","family":"Vano-Galvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7090-2187","authenticated-orcid":false,"given":"Martin","family":"Steinhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Nagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6053-6703","authenticated-orcid":false,"given":"Helen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6111-8008","authenticated-orcid":false,"given":"Ernest","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"issue":"2","key":"1260_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","volume":"14","author":"N Islam","year":"2015","unstructured":"Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14(2):81\u20139.","journal-title":"Autoimmun Rev"},{"issue":"7","key":"1260_CR2","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.autrev.2016.03.008","volume":"15","author":"A Gilhar","year":"2016","unstructured":"Gilhar A, Schrum AG, Etzioni A, Waldmann H, Paus R. Alopecia areata: animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies. Autoimmun Rev. 2016;15(7):726\u201335.","journal-title":"Autoimmun Rev"},{"key":"1260_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2147\/ITT.S266409","volume":"10","author":"P Suchonwanit","year":"2021","unstructured":"Suchonwanit P, Kositkuljorn C, Pomsoong C. Alopecia areata: an autoimmune disease of multiple players. Immunotargets Ther. 2021;10:299\u2013312.","journal-title":"Immunotargets Ther"},{"key":"1260_CR4","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"1260_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4103\/ijt.ijt_99_20","volume":"12","author":"LJ Burns","year":"2020","unstructured":"Burns LJ, Mesinkovska N, Kranz D, Ellison A, Senna MM. Cumulative life course impairment of alopecia areata. Int J Trichology. 2020;12(5):197\u2013204.","journal-title":"Int J Trichology"},{"issue":"1","key":"1260_CR6","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","volume":"20","author":"N Mesinkovska","year":"2020","unstructured":"Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20(1):S62\u20138.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"3","key":"1260_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13555-021-00512-0","volume":"11","author":"A Mostaghimi","year":"2021","unstructured":"Mostaghimi A, Napatalung L, Sikirica V, Winnette R, Xenakis J, Zwillich SH, et\u00a0al. Patient perspectives of the social, emotional and functional impact of alopecia areata: a systematic literature review. Dermatol Ther (Heidelb). 2021;11(3):867\u201383.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1260_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaad.2018.07.013","volume":"80","author":"S Lee","year":"2019","unstructured":"Lee S, Lee H, Lee CH, Lee WS. Comorbidities in alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(2):466\u201377.e16.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1260_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ajd.12941","volume":"60","author":"WC Cranwell","year":"2019","unstructured":"Cranwell WC, Lai VW, Photiou L, Meah N, Wall D, Rathnayake D, et\u00a0al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2019;60(2):163\u201370.","journal-title":"Australas J Dermatol"},{"issue":"6","key":"1260_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000254503","volume":"131","author":"T Ikeda","year":"1965","unstructured":"Ikeda T. A new classification of alopecia areata. Dermatologica. 1965;131(6):421\u201345.","journal-title":"Dermatologica"},{"issue":"9","key":"1260_CR11","volume":"12","author":"A Al-Ajlan","year":"2020","unstructured":"Al-Ajlan A, Alqahtani ME, Alsuwaidan S, Alsalhi A. Prevalence of alopecia areata in Saudi Arabia: cross-sectional descriptive study. Cureus. 2020;12(9): e10347.","journal-title":"Cureus"},{"key":"1260_CR12","unstructured":"US Food and Drug Administration. FDA Approves First Systemic Treatment for Alopecia Areata. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207924s006lbl.pdf. Accessed 18 July 2024."},{"issue":"6","key":"1260_CR13","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","volume":"14","author":"H Xu","year":"2019","unstructured":"Xu H, Jesson MI, Seneviratne UI, Lin TH, Sharif MN, Xue L, et\u00a0al. PF-06651600, a dual JAK3\/TEC family kinase inhibitor. ACS Chem Biol. 2019;14(6):1235\u201342.","journal-title":"ACS Chem Biol"},{"key":"1260_CR14","unstructured":"Pfizer. Litfulo (ritlecitinib) [prescribing information]. 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19638. Accessed 18 July 2024."},{"issue":"2","key":"1260_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s13555-020-00477-6","volume":"11","author":"J Macey","year":"2021","unstructured":"Macey J, Kitchen H, Aldhouse NVJ, Burge RT, Edson-Heredia E, McCollam JS, et\u00a0al. Dermatologist and patient perceptions of treatment success in alopecia areata and evaluation of clinical outcome assessments in Japan. Dermatol Ther (Heidelb). 2021;11(2):433\u201347.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1260_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/0974-7753.66920","volume":"2","author":"M Kumaresan","year":"2010","unstructured":"Kumaresan M. Intralesional steroids for alopecia areata. Int J Trichology. 2010;2(1):63\u20135.","journal-title":"Int J Trichology"},{"key":"1260_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ebiom.2016.03.036","volume":"7","author":"A Jabbari","year":"2016","unstructured":"Jabbari A, Cerise JE, Chen JC, Mackay-Wiggan J, Duvic M, Price V, et\u00a0al. Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. EBioMedicine. 2016;7:240\u20137.","journal-title":"EBioMedicine"},{"issue":"1","key":"1260_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","volume":"83","author":"N Meah","year":"2020","unstructured":"Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, et\u00a0al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83(1):123\u201330.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1260_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/jidsymp.2015.46","volume":"17","author":"AT Wagner","year":"2015","unstructured":"Wagner AT. Industry perspective on alopecia areata. J Investig Dermatol Symp Proc. 2015;17(2):67\u20139.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"3","key":"1260_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40257-014-0086-4","volume":"15","author":"M Hordinsky","year":"2014","unstructured":"Hordinsky M, Donati A. Alopecia areata: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3):231\u201346.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1260_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/ijt.ijt_53_17","volume":"9","author":"ST Hussain","year":"2017","unstructured":"Hussain ST, Mostaghimi A, Barr PJ, Brown JR, Joyce C, Huang KP. Utilization of mental health resources and complementary and alternative therapies for alopecia areata: a US survey. Int J Trichology. 2017;9(4):160\u20134.","journal-title":"Int J Trichology"},{"issue":"5","key":"1260_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4103\/ijt.ijt_57_19","volume":"11","author":"V Saoji","year":"2019","unstructured":"Saoji V, Kulkarni S, Madke B. Alopecia areata treated with oral azathioprine: a case series. Int J Trichology. 2019;11(5):219\u201322.","journal-title":"Int J Trichology"},{"issue":"1","key":"1260_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","volume":"78","author":"LC Strazzulla","year":"2018","unstructured":"Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et\u00a0al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15\u201324.","journal-title":"J Am Acad Dermatol"},{"key":"1260_CR24","unstructured":"Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. In: StatPearls. 2023. https:\/\/europepmc.org\/article\/NBK\/nbk531462. Accessed 19 July 2024."},{"key":"1260_CR25","unstructured":"Anderson P, Marwaha S, Piercy J, Law E, Wolk R, Schaefer G, et\u00a0al. Impact of scalp hair loss on treatment patterns and physician satisfaction with disease control for alopecia areata patients in Europe. 31st European Academy of Dermatology and Venereology Congress\u00a0Milan, Italy 2022. Abstract #1695."},{"issue":"10387","key":"1260_CR26","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et\u00a0al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401(10387):1518\u201329.","journal-title":"Lancet"},{"key":"1260_CR27","volume-title":"Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study","author":"C Tziotzios","year":"2023","unstructured":"Tziotzios C, Sinclair R, Lesiak A, Mehlis S, Kinoshita-Ise M, Tsianakas A, et\u00a0al. Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study. European Academy of Dermatology and Venereology Congress Berlin, Germany 2023. Abstract #2681."},{"issue":"6","key":"1260_CR28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/bjd\/ljad253","volume":"189","author":"B King","year":"2023","unstructured":"King B, Shapiro J, Ohyama M, Egeberg A, Piraccini BM, Craiglow B, et\u00a0al. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. Br J Dermatol. 2023;189(6):666\u201373.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1260_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","volume":"25","author":"B King","year":"2024","unstructured":"King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, et\u00a0al. Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program. Am J Clin Dermatol. 2024;25(2):299\u2013314.","journal-title":"Am J Clin Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01260-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T16:21:08Z","timestamp":1729009268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01260-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1260"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01260-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jennifer Fu has received consultation fees from Pfizer. Alexander Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, Bristol\u00a0Myers Squibb, AbbVie, Janssen, and Boehringer Ingelheim and has received honoraria for work as a consultant and\/or speaker from AbbVie, Almirall, LEO Pharma, Zuellig Pharma, Galapagos NV, SUN Pharmaceuticals, Samsung Bioepis, Pfizer, Eli Lilly, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol\u00a0Myers Squibb, McNeil Consumer Healthcare, Horizon Therapeutics, Boehringer Ingelheim, and Janssen. Susan Holmes is an investigator for Pfizer and has undertaken paid consultancy work for Pfizer. Sergio Vano-Galvan has received research funding and honoraria for work as a consultant and\/or speaker from Pfizer and Eli Lilly. Martin Steinhoff has received honoraria or investigative or consultation fees from or was an investigator for AbbVie, Almirall, Avon, Algorithm, Allergan, Bayer Health, Baiersdorf, Bristol\u00a0Myers\u00a0Squibb, Celgene, Chugai, Ducray, Eli Lilly, Galderma, Genentech, GSK, Incyte, Janssen, Johnson & Johnson, Kiniksa, LEO Pharma, L\u2019Oreal, Maruho, Menlo Therapeutics, Mitsubishi, Novartis, Pfizer, Pierre-Fabre, Qatar Pharma, Regeneron, Sanofi, Toray, Trevi, Vertex, and ZymoGenetics. Roger Edwards is an employee of Health Services Consulting Corporation and received consultancy fees from Pfizer in connection with this study. Gianluca Bonfanti is an employee of Engineering Ingegneria Informatica, which is a paid subcontractor to Health Services Consulting Corporation. Ranjit Nagra, Robert Wolk, Helen Tran, and Ernest Law are employees of, and hold stock or stock options in, Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocol was reviewed and approved by the institutional review boards or ethics committees of the participating institutions. The study was conducted in accordance with the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of Medical Sciences 2002), International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use Guideline for Good Clinical Practice, and Helsinki Declaration of 1964 and its later amendments. Written informed consent was obtained from each patient, patient\u2019s parent, or patient\u2019s legal representative to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}